Greek cuts could drive business melt-down and drugs shortages, industry claims
This article was originally published in Scrip
The Greek pharmaceutical market faces "dramatic consequences" of upheavals designed to cut the drugs bill and avoid a sovereign debt default. The consequences, says the SFEE (the Hellenic Association of Pharmaceutical Companies), could include companies going out of business, large job losses, distribution chains being disrupted and serious shortages of medicines. SFEE has issued double warning about a recent new law and the outlook for the government bonds pharma firms were forced to accept in lieu of cash payments for debts owed to them by public hospitals (scripintelligence.com, 13 March 2012).
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.